Your browser doesn't support javascript.
loading
Quadruple therapies are superior to standard triple therapy for Helicobacter pylori first-line eradication in Chile. / Terapias cuádruples son superiores a terapia triple estándar en primera línea de erradicación de Helicobacter pylori en Chile.
Reyes, Diego; Ortiz, Javier; Fuentes-López, Eduardo; Budnik, Sigall; Gándara, Vicente; Gallardo, Andrea; Seydewitz, María Francisca; Candia, Roberto; Vargas, José Ignacio; Rollan, María Paz; Godoy, Javiera; Rollan, Antonio; Mansilla, Rodrigo; Arenas, Alex; Chahuán, Javier; Espino, Alberto; Pizarro, Margarita; Riquelme, Arnoldo.
Afiliação
  • Reyes D; Departamento de Medicina Interna, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Electronic address: dmreyes@uc.cl.
  • Ortiz J; Departamento de Medicina Interna, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Fuentes-López E; Departamento de Ciencias de la Salud, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Budnik S; Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Gándara V; Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Gallardo A; Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Seydewitz MF; Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Candia R; Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Vargas JI; Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; Division of Gastroenterology, Department of Medicine, Saint Michael's Hospital, University of Toronto, Toronto, Canadá.
  • Rollan MP; Facultad de Medicina, Clínica Alemana-Universidad del Desarrollo, Santiago, Chile.
  • Godoy J; Facultad de Medicina, Clínica Alemana-Universidad del Desarrollo, Santiago, Chile.
  • Rollan A; Departamento de Gastroenterología, Clínica Alemana, Santiago, Chile.
  • Mansilla R; Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; Departamento de Gastroenterología, Hospital de Puerto Montt, Puerto Montt, Chile.
  • Arenas A; Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; División de Gastroenterología, Departamento de Medicina, Complejo Asistencial Dr. Sótero del Río, Santiago, Chile.
  • Chahuán J; Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Espino A; Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Pizarro M; Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Riquelme A; Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; Departamento de Ciencias de la Salud, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Gastroenterol Hepatol ; 45(7): 515-523, 2022.
Article em En, Es | MEDLINE | ID: mdl-34890721
INTRODUCTION: Helicobacter pylori infection affects approximately 70% of the Chilean population. It is a public health problem whose eradication treatment is part of the explicit health guarantees in Chile. OBJECTIVES: Characterize the most widely used H. pylori first-line eradication therapies in our environment and evaluate their efficacy. METHODS: A retrospective observational study was carried out where, in patients with certified H. pylori infection, the eradication therapy indicated by the treating physician, its efficacy, adherence and adverse effects, in addition to the eradication certification method used, were evaluated. RESULTS: 242 patients and 4 main therapies were analyzed: standard triple therapy, dual therapy, concomitant therapy, and bismuth quadruple therapy. Eradication rates of 81.9% (95% CI 74.44-87.63), 88.5% (95% CI 73.13-95.67), 93.7% (95% CI 78.07-98.44) and 97.6% (95% CI 84.81-99.67) were observed respectively, with concomitant therapy (RR: 1.14; 95% CI 1.01-1.29; p=.028) and quadruple therapy with bismuth (RR: 1.19; 95% CI 1.09-1.31; p<.001) being significantly more effective than standard triple therapy. Regarding the rate of reported adverse effects, it was 58.5% (95% CI 50.66-65.92), 35.4% (95% CI 24.6-48.11), 22.9% (95% CI 81-37.14) and 63.4% (95% CI 47.8-76.64), having the dual and concomitant therapy significantly fewer adverse effects compared with standard therapy. CONCLUSIONS: Quadruple therapies are superior to standard triple therapy and should be considered as first-line treatment in Chile. Dual therapy is promising. More studies will be required to determine which therapies are most cost-effective.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Helicobacter pylori / Infecções por Helicobacter Tipo de estudo: Observational_studies Limite: Humans País/Região como assunto: America do sul / Chile Idioma: En / Es Revista: Gastroenterol Hepatol Ano de publicação: 2022 Tipo de documento: Article País de publicação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Helicobacter pylori / Infecções por Helicobacter Tipo de estudo: Observational_studies Limite: Humans País/Região como assunto: America do sul / Chile Idioma: En / Es Revista: Gastroenterol Hepatol Ano de publicação: 2022 Tipo de documento: Article País de publicação: Espanha